| |
|
| |
| 今井 浩三 |
東京大学医科学研究所 特任教授 |
| Comparing antibody and small-molecule therapies for cancer. Imai K, Takaoka A. Nature Rev Cancer, 6: 714-727, 2006. |
| Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Suzuki H, Imai K, et al. Nat Genet, 36(4): 417-422, 2004. |
| Integration of interferon-α/β signalling to p53 responses in tumor suppression and antiviral defence. Takaoka A, Imai K, et al. Nature, 424: 516-523, 2003. |
|
| |
| 大津 敦 |
独立行政法人国立がん研究センター東病院
臨床開発センター長 |
| 腫瘍内科 |
| Ohtsu A, Shah M, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-Line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III Study. J Clin Oncol, 29(30):3968-3976, 2011 |
| 2) Bang YJ, Van Cutsem E, Ohtsu A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010 |
| 3) Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol, 21: 54-59, 2003 |
|
| |
| 清木 元治 |
東京大学医科学研究所 教授 |
| 分子生物学 |
| Targeting the Warburg effect that arises in tumor cells expressing membrane type-1 matrix metalloproteinase. SAKAMOTO. T., D. NIIYA, and M. SEIKI. J. Biol. Chem. 2011 April. 286, 14691-14704 |
| A matrix metalloproteinase expressed on the surface of invasive tumor cells. SATO, H., T. TAKINO, Y. OKADA, J. CAO, A. SHINAGAWA, E. YAMAMOTO, and M. SEIKI, Nature. 1994 July; 370, 61-65, |
| Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. SEIKI, M., S. HATTORI, Y. HIRAYAMA, and M. YOSHIDA |
|
|
| 中西 洋一 |
九州大学大学院医学研究院 教授 |
| 臨床腫瘍学・呼吸器内科学・臨床試験 |
IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population.
Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y.
J Thorac Oncol 5:299-304,2010 |
Tetracycline-inducible promoter-based conditionally replicative adenoviruses for the control of viral replication.
Zhang H, Takayama K, Zhang L, Uchino J, Harada A, Harada T, Hisasue J, Nakagaki N, Zhou C, Nakanishi Y
Cancer Gene Ther 16:415-422,2009 |
A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer.
N Ebi, H Semba, S Tokunaga, K Takayama, H Wataya, T Kuraki, H Yamamoto, S Akamine, I Okamoto, Y Nakanishi. (Lung Oncology Group in Kyushu Japan)
J Thorac Oncol 10:1166-1171, 2008 |
|
| |
| 野田 哲生 |
公益財団法人がん研究会がん研究所 所長 |
|
| ○ |
| 福岡 正博 |
和泉市立病院がんセンター センター長 |
| 臨床腫瘍学 |
| Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. J Clin Oncol 29(21): 2866-74, 2011. |
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. N Engl J Med. 361(10): 947-57, 2009. |
| Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst.83(12): 855-61, 1991. |
|
| |
| 森山 紀之 |
独立行政法人国立がん研究センター
がん予防・検診研究センター長 |
| 画像診断 |
Ditection Failures in Spiral CT Screening for Lung Cancer:Analysis CT Findings. N.Moriyama. Ragiology. 1999; 212(1):61-66.
Development of Helical CT and Assessment of Its Clinical Value. N.Moriyama. Medical Review. 1994; 49:579-581. |
| 「肝CT読影の実際」森山紀之 金原出版 (1986). |
|
| |
| 高橋 利忠 |
健康科学総合センター 名誉センター長 |
| 腫瘍免疫学 |
Thymus-leukemia antigen (TL) as a major histocompatibility complex (MHC) class Ib molecule and tumor-specific antigen.
Tsujimura, K., Obata, Y., Takahashi, T.
Cancer Sci.2004; 95: 469-474. |
Kawase,T.,Akatsuka,Y.,Torikai,H.,Morishima,S.,Oka,A.,Tsujimura,A.,
Miyazaki,M.,Tsujumura,K.,Miyamura,K.,Ogawa,S.,Inoko,H.,
Morishima,Y., Kodera,y., Kuzushima,K.., Takahashi,T.
Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen.
Blood. 2007; 110: 1055-1063. |
A Minor histocompatibility antigen as targets for immunotherapy utilizing allogeneic immune reactions.
Akatuka, Y., Morishima, Y., Kuzushima, K., Kodera, Y., Takahashi, T
Cancer Sci. 2009;78:1139-1146 |
|
